The Patent Finder

Universite de Paris

24 patents currently held · Updated Nov 16, 2026
259 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

Recorded as renamed to Université Paris Cité (2022)

0
Ending by 2030
Feb 2035
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Feb 13, 2027
    The maintenance fee for Combination of bezafibrate and of resveratrol or resveratrol derivatives for the treatment and prevention of diseases involving a mitochondrial energy dysfunction (US 10,376,484) comes due Feb 13, 2027. Unpaid by Aug 13, 2027, it lapses early.
  • 2 fees due Jun 26, 2027

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 18, 2026
  • 5 terms have ended since Aug 18, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 10,376,484Combination of bezafibrate and of resveratrol or resveratrol derivatives for the treatment and prevention of diseases involving a mitochondrial energy dysfunction
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,383,004Methods for Adhering Tissue Surfaces and Materials and Biomedical Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 10,710,045Capsules Containing Mammalian Cells
In force
 · High confidence
In forceHigh confidence
US 12,427,141BYL719 (ALPELISIB) for Use in the Treatment of PIK3CA-RELATED Overgrowth Spectrum (Pros-Cloves Syndrome)
In force
 · High confidence
In forceHigh confidence
US 10,842,776Hycanthone Derivatives and Primaquine Derivatives for Use in the Prevention And/Or the Treatment of Disorders Associated to Gammaherpesvirus
In force
 · High confidence
In forceHigh confidence
US 11,638,723Method for Generating T Cells Progenitors
In force
 · High confidence
In forceHigh confidence
US 11,642,376Method for Generating T Cell Progenitors
In force
 · High confidence
In forceHigh confidence
US 12,599,662Methods and Compositions for Treating Cancers
In force
 · High confidence
In forceHigh confidence
US 12,778,952Infigratinib for Treatment of FGFR3-RELATED Skeletal Diseases During Pregnancy
In force
 · High confidence
In forceHigh confidence
US 11,854,801Method and Device for Depositing a Nano-Object
In force
 · High confidence
In forceHigh confidence
10 of 24 patents shown.
Pro members see all 24.
Pro members: see all 24 patents
Also on record, not counted in the 24: 259 patents in force now held by others · 55 lapsed for an unpaid fee · 9 ended at full term · 1 past the fee grace period. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

44 pending · 66 abandoned

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited